title: Evolution of glycated haemoglobin in adults on growth hormone replacement therapy.
abstract: OBJECTIVE
  To evaluate the effects of GH replacement therapy (GHR) for 3 years on glycated haemoglobin (HbA1c) and on the presence of dysglycaemia at any time during follow-up in Spanish adult patients with growth hormone deficiency (GHD).
  
  
  METHODS
  A retrospective study of 41 patients with GHD was conducted using baseline and long-term data. Changes in HbA1c values during the first 3 years of GHR were studied in both the overall population and patients with or without dysglycaemia during follow-up. Dysglycaemia was defined as FPG ≥ 100 mg/dl and/or HbA1c ≥ 5.7%.
  
  
  RESULTS
  Mean HbA1c value (5.4 ± 0.4% at baseline) increased during the first and second years of GHR (HbA1c 5.5 ± 0.4%, p=0.05, and 5.5 ± 0.4%, p=0.006 respectively). This increase was not maintained during the third year (HbA1c 5.4 ± 0.3%, p=0.107) of GHR. Twenty-eight patients (68.2%) had dysglycaemia during follow-up, 9 of them since baseline. In the 19 patients without baseline dysglycaemia, HbA1c increased during the first year and remained stable in the next 2 years (mean HbA1c 5.2 ± 0.4% at baseline; 5.5 ± 0.4% at 1 year, p<0.050; 5.4 ± 0.4% at 2 years, p=0.004, and 5.4 ± 0.4% at 3 years, p=0.016). In the 9 patients with baseline dysglycaemia, HbA1c did not significantly change during the 3 years of GHR therapy.
  
  
  CONCLUSIONS
  HbA1c values increased during the first 2 years of GHR therapy. In patients with no dysglycaemia before treatment, HbA1c steadily increased over the 3 years. However, it did not change in patients with baseline dysglycaemia.
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: paprch@yahoo.com.
authors.forename: Paola
authors.initials: P
authors.lastname: Andrea Parra R
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: beatriz.barquiel@gmail.com.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Barquiel A
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: afernamed@hotmail.com.
authors.forename: Alberto
authors.initials: A
authors.lastname: Fernández M
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: lp02@hotmail.com.
authors.forename: Laura
authors.initials: L
authors.lastname: Pérez F
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: lecum74@hotmail.com.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Lecumberri S
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: mayll_c@hotmail.com.
authors.forename: Mary
authors.initials: M
authors.lastname: Gaby Llaro C
authors.affiliation: Endocrinology Department, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain. Electronic address: escola.cristina@gmail.com.
authors.forename: Cristina
authors.initials: C
authors.lastname: Álvarez-Escolá
mesh_terms: D000328:Adult; D018450:Disease Progression; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced; D007018:Hypopituitarism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D006442:Glycated Hemoglobin; D019382:Human Growth Hormone
keywords: Diabetes mellitus; Dysglycaemia; Glycated haemoglobin; Growth hormone; diabetes mellitus; disglucemia; hemoglobina glicada; hormona de crecimiento